- Details
- At the 2024 UCSF-UCLA PSMA Conference, Amar Kishan presents on metastasis-directed therapy (MDT) for oligometastatic prostate cancer, highlighting its potential to delay systemic therapy and improve progression-free survival (PFS) as evidenced by trials like STOMP, ORIOLE, EXTEND, and ARTO. Dr. Kishan emphasizes the role of PSMA PET imaging in identifying MDT candidates and calls for further resea...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Matthias Eiber advocates for standardized reporting in PSMA PET imaging, underscoring its significance in improving clinical and research communication, with frameworks like PROMISE, PSMA-RADS, PPP, and RECIP enhancing treatment decision-making and lesion assessment. Dr. Eiber envisions future advancements in validating these frameworks' prognostic value and...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Michael Morris highlights the importance of PSMA PET in prostate cancer management, acknowledging the regulatory framework established by pivotal trials that led to FDA approval for PSMA PET tracers. Dr. Morris discusses the challenges of interpreting PSMA PET results, the need for consensus in its application, particularly in biochemical recurrence and radio...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy for prostate cancer, particularly highlighting lutetium PSMA-617's efficacy in improving survival and quality of life as shown in the VISION trial. Dr. Morris stresses the importance of further research to refine patient s...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Robert Reiter highlights the transformative impact of PSMA PET imaging on the pre-prostatectomy process, showcasing its superiority in staging accuracy, metastatic disease detection, and offering insights into tumor biology for informed management. Dr. Reiter discusses PSMA PET's adjunctive role to MRI in cancer detection, its prognostic value in predicting b...
|
- Details
- In a conversation with Phillip Koo, Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. They explore the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes. Emmett emphas...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Nicholas Nickols elucidates the evolution of prostate cancer imaging, crediting PSMA PET with transitioning it into a highly imaged disease, and discusses its integration into radiotherapy planning for enhanced precision and personalization in treatment. Dr. Nickols highlights the role of PSMA PET in refining radiation oncology through improved target identif...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Thomas Hope explores the impact of PSMA PET imaging on prostate cancer care, emphasizing the ProPSMA trial's comparison of PSMA PET to conventional imaging and the PreRP trial's pursuit of FDA approval, highlighting their roles in enhancing diagnosis and treatment. Dr. Hope concludes with a patient case to illustrate how these studies, through their design, f...
|
- Details
- Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...
|
- Details
- At the 2024 UCSF-UCLA PSMA Conference, Peter Carroll highlights the shift in prostate cancer treatment from surgery for low-risk patients to active surveillance and targeted treatment for higher-risk groups, emphasizing the importance of novel imaging like PSMA PET in improving outcomes. He advocates for personalized treatment strategies based on detailed risk assessments and the potential benefit...
|
